General Information of the Ferroptosis Regulator (ID: REG10311)
Regulator Name Parkinson disease protein 7 (PARK7)
Synonyms
Maillard deglycase
    Click to Show/Hide
Gene Name PARK7
Gene ID 11315
Regulator Type Protein coding
Uniprot ID Q99497
Sequence
MASKRALVILAKGAEEMETVIPVDVMRRAGIKVTVAGLAGKDPVQCSRDVVICPDASLED
AKKEGPYDVVVLPGGNLGAQNLSESAAVKEILKEQENRKGLIAAICAGPTALLAHEIGFG
SKVTTHPLAKDKMMNGGHYTYSENRVEKDGLILTSRGPGTSFEFALAIVEALNGKEVAAQ
VKAPLVLKD

    Click to Show/Hide
Family Peptidase C56 family
Function
Multifunctional protein with controversial molecular function which plays an important role in cell protection against oxidative stress and cell death acting as oxidative stress sensor and redox- sensitive chaperone and protease. It is involved in neuroprotective mechanisms like the stabilization of NFE2L2 and PINK1 proteins, male fertility as a positive regulator of androgen signaling pathway as well as cell growth and transformation through, for instance, the modulation of NF-kappa-B signaling pathway. Has been described as a protein and nucleotide deglycase that catalyzes the deglycation of the Maillard adducts formed between amino groups of proteins or nucleotides and reactive carbonyl groups of glyoxals. But this function is rebuted by other works. As a protein deglycase, repairs methylglyoxal- and glyoxal-glycated proteins, and releases repaired proteins and lactate or glycolate, respectively. Deglycates cysteine, arginine and lysine residues in proteins, and thus reactivates these proteins by reversing glycation by glyoxals. Acts on early glycation intermediates (hemithioacetals and aminocarbinols), preventing the formation of advanced glycation endproducts (AGE) that cause irreversible damage. Also functions as a nucleotide deglycase able to repair glycated guanine in the free nucleotide pool (GTP, GDP, GMP, dGTP) and in DNA and RNA. Is thus involved in a major nucleotide repair system named guanine glycation repair (GG repair), dedicated to reversing methylglyoxal and glyoxal damage via nucleotide sanitization and direct nucleic acid repair. Protects histones from adduction by methylglyoxal, controls the levels of methylglyoxal- derived argininine modifications on chromatin. Able to remove the glycations and restore histone 3, histone glycation disrupts both local and global chromatin architecture by altering histone-DNA interactions as well as histone acetylation and ubiquitination levels. Displays a very low glyoxalase activity that may reflect its deglycase activity. Eliminates hydrogen peroxide and protects cells against hydrogen peroxide-induced cell death. Required for correct mitochondrial morphology and function as well as for autophagy of dysfunctional mitochondria. Plays a role in regulating expression or stability of the mitochondrial uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the neurons via L-type channels during pacemaking. Regulates astrocyte inflammatory responses, may modulate lipid rafts-dependent endocytosis in astrocytes and neuronal cells. In pancreatic islets, involved in the maintenance of mitochondrial reactive oxygen species (ROS) levels and glucose homeostasis in an age- and diet dependent manner. Protects pancreatic beta cells from cell death induced by inflammatory and cytotoxic setting. Binds to a number of mRNAs containing multiple copies of GG or CC motifs and partially inhibits their translation but dissociates following oxidative stress. Metal-binding protein able to bind copper as well as toxic mercury ions, enhances the cell protection mechanism against induced metal toxicity. In macrophages, interacts with the NADPH oxidase subunit NCF1 to direct NADPH oxidase-dependent ROS production, and protects against sepsis.

    Click to Show/Hide
HGNC ID
HGNC:16369
KEGG ID hsa:11315
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
PARK7 can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Unspecific Target [Unspecific Target]
In total 2 item(s) under this target
Experiment 1 Reporting the Ferroptosis Target of This Regulator [1]
Responsed Disease Lung cancer ICD-11: 2C25
Responsed Drug 1,1-(Decane-1,10-diyl)bis(5-fluoroindoline-2,3-dione) Investigative
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model
NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
PC-9 cells Lung adenocarcinoma Homo sapiens CVCL_B260
MDA-MB-231 cells Breast adenocarcinoma Homo sapiens CVCL_0062
HCC1937 cells Breast ductal carcinoma Homo sapiens CVCL_0290
BEL-7402 cells Endocervical adenocarcinoma Homo sapiens CVCL_5492
Hep-G2 cells Hepatoblastoma Homo sapiens CVCL_0027
786-O cells Renal cell carcinoma Homo sapiens CVCL_1051
RCC4 cells Clear cell renal cell carcinoma Homo sapiens CVCL_0498
HEK-293T cells Normal Homo sapiens CVCL_0063
In Vivo Model
Tumors were established by injecting 200 uL of H1299 cell suspensions (2 x 106) into BALB/c female athymic nude mice (5 weeks, National Rodent Laboratory Animal Resource, Shanghai, China). When the tumor volume reached an average size of 80 mm3, tumor-bearing mice were subsequently randomly divided into three groups (n = 7 for each group). STK or DM10 was intratumorally administered as a single agent in mouse tumors at a dose of 30 or 15 mg/kg only once.

    Click to Show/Hide
Response regulation The PARK7 gene (encode DJ-1 protein) was first discovered as an oncogene and later found to be a causative gene for autosomal recessive early onset Parkinson's disease. 1,1-(Decane-1,10-diyl)bis(5-fluoroindoline-2,3-dione) (DM10) is identified as a potent inhibitor targeting DJ-1 homodimer with the potential as sensitizing agent for other anticancer drugs.
Experiment 2 Reporting the Ferroptosis Target of This Regulator [3]
Responsed Disease Hepatocellular carcinoma ICD-11: 2C12
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model
Huh-7 cells Hepatocellular carcinoma Homo sapiens CVCL_0336
HCCLM3 cells Adult hepatocellular carcinoma Homo sapiens CVCL_6832
THLE-2 cells Normal Homo sapiens CVCL_3803
Hep 3B2.1-7 cells Hepatocellular carcinoma Homo sapiens CVCL_0326
SK-HEP-1 cells Liver and intrahepatic bile duct epithelial neoplasm Homo sapiens CVCL_0525
Hep-G2 cells Hepatoblastoma Homo sapiens CVCL_0027
In Vivo Model
Six-week-old BALB/c female athymic nude mice (SJA Laboratory Animal Co., Ltd, China) were used to construct the xenograft. The mice were randomly grouped: (1) shNC + vehicle; (2) shNC + Erastin; (3) shWTAP + Erastin; (4) shcircCMTM3 + Erastin. Briefly, HCC cells with stable silenced WTAP and circCMTM3 (2 x 106 in 0.1 mL PBS) were injected into the left flank of the mice subcutaneously. Once the tumor size reached approximately > 60 mm3, mice in the groups (2), (3), and (4) were injected with 15 mg/kg erastin. Erastin was injected twice a day for a period of time.

    Click to Show/Hide
Response regulation CircCMTM3 promoted the carcinogenesis through inhibiting ferroptosis by recruiting IGF2BP1 to increase PARK7 stability in hepatocellular carcinoma (HCC), suggesting that cicrCMTM3 may be an important marker for HCC treatment.
Prostaglandin G/H synthase 2 (PTGS2) [Driver; Marker]
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis Target of This Regulator [2]
Target for Ferroptosis Marker
Responsed Disease Parkinson disease ICD-11: 8A00
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model
NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
A-549 cells Lung adenocarcinoma Homo sapiens CVCL_0023
PANC-1 cells Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
NCI-H292 cells Lung mucoepidermoid carcinoma Homo sapiens CVCL_0455
NCI-H838 cells Lung adenocarcinoma Homo sapiens CVCL_1594
786-O cells Renal cell carcinoma Homo sapiens CVCL_1051
KHOS cells Osteosarcoma Homo sapiens CVCL_2546
A2780 cells Ovarian endometrioid adenocarcinoma Homo sapiens CVCL_0134
HEK-293T cells Normal Homo sapiens CVCL_0063
In Vivo Model
Tumors were established by a subcutaneous injection of shRNA (control or DJ-1 KD) transfected H1299 cells (1,000,000/200 uL) into BALB/c female athymic nude mice (5 weeks, National Rodent Laboratory Animal Resource, Shanghai, China). Twelve days after injection, mice were randomly allocated into different groups and treated with vehicle (0.625% DMSO/99.375% HBSS (pH = 2)) or 30 mg/kg PE (tail intravenous injection, once every other day) for 16 days before the final tumor size was measured in all groups.

    Click to Show/Hide
Response regulation KD of DJ-1 (PARK7) increases ferroptosis as PTGS2 levels increased. DJ-1 mutant neuronal cells experience high levels of ferroptosis, which might establish a potential mechanism via which DJ-1 could regulate early-onset recessive Parkinsons disease.
Lung cancer [ICD-11: 2C25]
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [1]
Target Regulator Parkinson disease protein 7 (PARK7) Protein coding
Responsed Drug 1,1-(Decane-1,10-diyl)bis(5-fluoroindoline-2,3-dione) Investigative
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model
NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
PC-9 cells Lung adenocarcinoma Homo sapiens CVCL_B260
MDA-MB-231 cells Breast adenocarcinoma Homo sapiens CVCL_0062
HCC1937 cells Breast ductal carcinoma Homo sapiens CVCL_0290
BEL-7402 cells Endocervical adenocarcinoma Homo sapiens CVCL_5492
Hep-G2 cells Hepatoblastoma Homo sapiens CVCL_0027
786-O cells Renal cell carcinoma Homo sapiens CVCL_1051
RCC4 cells Clear cell renal cell carcinoma Homo sapiens CVCL_0498
HEK-293T cells Normal Homo sapiens CVCL_0063
In Vivo Model
Tumors were established by injecting 200 uL of H1299 cell suspensions (2 x 106) into BALB/c female athymic nude mice (5 weeks, National Rodent Laboratory Animal Resource, Shanghai, China). When the tumor volume reached an average size of 80 mm3, tumor-bearing mice were subsequently randomly divided into three groups (n = 7 for each group). STK or DM10 was intratumorally administered as a single agent in mouse tumors at a dose of 30 or 15 mg/kg only once.

    Click to Show/Hide
Response regulation The PARK7 gene (encode DJ-1 protein) was first discovered as an oncogene and later found to be a causative gene for autosomal recessive early onset Parkinson's disease. 1,1-(Decane-1,10-diyl)bis(5-fluoroindoline-2,3-dione) (DM10) is identified as a potent inhibitor targeting DJ-1 homodimer with the potential as sensitizing agent for other anticancer drugs.
Parkinson disease [ICD-11: 8A00]
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [2]
Target Regulator Parkinson disease protein 7 (PARK7) Protein coding
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model
NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
A-549 cells Lung adenocarcinoma Homo sapiens CVCL_0023
PANC-1 cells Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
NCI-H292 cells Lung mucoepidermoid carcinoma Homo sapiens CVCL_0455
NCI-H838 cells Lung adenocarcinoma Homo sapiens CVCL_1594
786-O cells Renal cell carcinoma Homo sapiens CVCL_1051
KHOS cells Osteosarcoma Homo sapiens CVCL_2546
A2780 cells Ovarian endometrioid adenocarcinoma Homo sapiens CVCL_0134
HEK-293T cells Normal Homo sapiens CVCL_0063
In Vivo Model
Tumors were established by a subcutaneous injection of shRNA (control or DJ-1 KD) transfected H1299 cells (1,000,000/200 uL) into BALB/c female athymic nude mice (5 weeks, National Rodent Laboratory Animal Resource, Shanghai, China). Twelve days after injection, mice were randomly allocated into different groups and treated with vehicle (0.625% DMSO/99.375% HBSS (pH = 2)) or 30 mg/kg PE (tail intravenous injection, once every other day) for 16 days before the final tumor size was measured in all groups.

    Click to Show/Hide
Response regulation KD of DJ-1 (PARK7) increases ferroptosis as PTGS2 levels increased. DJ-1 mutant neuronal cells experience high levels of ferroptosis, which might establish a potential mechanism via which DJ-1 could regulate early-onset recessive Parkinsons disease.
Hepatocellular carcinoma [ICD-11: 2C12]
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [3]
Target Regulator Parkinson disease protein 7 (PARK7) Protein coding
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model
Huh-7 cells Hepatocellular carcinoma Homo sapiens CVCL_0336
HCCLM3 cells Adult hepatocellular carcinoma Homo sapiens CVCL_6832
THLE-2 cells Normal Homo sapiens CVCL_3803
Hep 3B2.1-7 cells Hepatocellular carcinoma Homo sapiens CVCL_0326
SK-HEP-1 cells Liver and intrahepatic bile duct epithelial neoplasm Homo sapiens CVCL_0525
Hep-G2 cells Hepatoblastoma Homo sapiens CVCL_0027
In Vivo Model
Six-week-old BALB/c female athymic nude mice (SJA Laboratory Animal Co., Ltd, China) were used to construct the xenograft. The mice were randomly grouped: (1) shNC + vehicle; (2) shNC + Erastin; (3) shWTAP + Erastin; (4) shcircCMTM3 + Erastin. Briefly, HCC cells with stable silenced WTAP and circCMTM3 (2 x 106 in 0.1 mL PBS) were injected into the left flank of the mice subcutaneously. Once the tumor size reached approximately > 60 mm3, mice in the groups (2), (3), and (4) were injected with 15 mg/kg erastin. Erastin was injected twice a day for a period of time.

    Click to Show/Hide
Response regulation CircCMTM3 promoted the carcinogenesis through inhibiting ferroptosis by recruiting IGF2BP1 to increase PARK7 stability in hepatocellular carcinoma (HCC), suggesting that cicrCMTM3 may be an important marker for HCC treatment.
1,1-(Decane-1,10-diyl)bis(5-fluoroindoline-2,3-dione) [Investigative]
In total 1 item(s) under this drug
Experiment 1 Reporting the Ferroptosis-centered Drug Response [1]
Drug for Ferroptosis Inducer
Response Target Unspecific Target
Responsed Disease Lung cancer ICD-11: 2C25
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model
NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
PC-9 cells Lung adenocarcinoma Homo sapiens CVCL_B260
MDA-MB-231 cells Breast adenocarcinoma Homo sapiens CVCL_0062
HCC1937 cells Breast ductal carcinoma Homo sapiens CVCL_0290
BEL-7402 cells Endocervical adenocarcinoma Homo sapiens CVCL_5492
Hep-G2 cells Hepatoblastoma Homo sapiens CVCL_0027
786-O cells Renal cell carcinoma Homo sapiens CVCL_1051
RCC4 cells Clear cell renal cell carcinoma Homo sapiens CVCL_0498
HEK-293T cells Normal Homo sapiens CVCL_0063
In Vivo Model
Tumors were established by injecting 200 uL of H1299 cell suspensions (2 x 106) into BALB/c female athymic nude mice (5 weeks, National Rodent Laboratory Animal Resource, Shanghai, China). When the tumor volume reached an average size of 80 mm3, tumor-bearing mice were subsequently randomly divided into three groups (n = 7 for each group). STK or DM10 was intratumorally administered as a single agent in mouse tumors at a dose of 30 or 15 mg/kg only once.

    Click to Show/Hide
Response regulation The PARK7 gene (encode DJ-1 protein) was first discovered as an oncogene and later found to be a causative gene for autosomal recessive early onset Parkinson's disease. 1,1-(Decane-1,10-diyl)bis(5-fluoroindoline-2,3-dione) (DM10) is identified as a potent inhibitor targeting DJ-1 homodimer with the potential as sensitizing agent for other anticancer drugs.
References
Ref 1 Bis-isatin derivatives: design, synthesis, and biological activity evaluation as potent dimeric DJ-1 inhibitors. Acta Pharmacol Sin. 2021 Jul;42(7):1160-1170. doi: 10.1038/s41401-020-00600-5. Epub 2021 Jan 25.
Ref 2 DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase. Nat Commun. 2020 Mar 6;11(1):1251. doi: 10.1038/s41467-020-15109-y.
Ref 3 WTAP-mediated m6A modification on circCMTM3 inhibits hepatocellular carcinoma ferroptosis by recruiting IGF2BP1 to increase PARK7 stability. Dig Liver Dis. 2023 Jul;55(7):967-981. doi: 10.1016/j.dld.2022.12.005. Epub 2022 Dec 30.